Sanofi (SNY)

38.84
0.04 0.10
NYSE : Health Technology
Prev Close 38.88
Open 39.01
Day Low/High 38.97 / 39.04
52 Wk Low/High 37.43 / 50.65
Volume 57.90K
Avg Volume 1.21M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 95.77B
EPS 1.70
P/E Ratio 20.91
Div & Yield 1.25 (2.85%)
Sanofi to Pay for Drug Overcharges

Sanofi to Pay for Drug Overcharges

Sanofi SA agreed to a U.S. Department of Justice a $19.8 million fine for overcharging the U.S. Department of Veteran Affairs.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron, Sanofi Score Eczema Drug Approval

Regeneron and Sanofi will launch Dupixent with a gross sticker price of $37,000 per year, before insurance discounts and rebates.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Stocks Fall as House Leaders Delay Health Care Vote

Stocks Fall as House Leaders Delay Health Care Vote

Stocks fall on Thursday afternoon after House leaders delay a highly anticipated vote on the Republicans' repeal-and-replace health care bill.

Sanofi Said to Be Near $1 Billion Deal for Flexion

Sanofi Said to Be Near $1 Billion Deal for Flexion

Flexion is an arthritis-focused biotech company.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

Amgen: Clinical Trials Set Stage for Further Upside

Amgen: Clinical Trials Set Stage for Further Upside

This biotech name shows no sign of slowing down.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA

Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.

15 Remakes and Sequels Coming to the Silver Screen in 2017

15 Remakes and Sequels Coming to the Silver Screen in 2017

Hollywood's lack of originality shines through with 15 remakes and sequels this year.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Sanofi's Base Pattern Should Make Investors Happy

Sanofi's Base Pattern Should Make Investors Happy

SNY has become much stronger since late October; buy here and above $44.

Clovis, Tesaro Soar on Astrazeneca Phase Three News

Clovis, Tesaro Soar on Astrazeneca Phase Three News

AstraZeneca shares, meanwhile, were less-than-moved by the news.

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

DexCom Is a Great Healthcare Stock to Buy Now

DexCom Is a Great Healthcare Stock to Buy Now

The continuous glucose monitor maker is an excellent growth opportunity.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor

The Auvi-Q was released Feb. 14, but it's unclear whether patients will break up with their current option, EpiPen, for something new.

Biotech Tesaro Climbs on Takeout Reports

Biotech Tesaro Climbs on Takeout Reports

The company's shares were up 14% on rumors that it is working with investment banks to consider a sale.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Hagens Berman: Insulin Manufacturers Hit With Class-Action Lawsuit Over Drug Price Inflation Scheme And RICO Violations - Time To Break Up The Insulin Racket

People living with diabetes have filed a groundbreaking class-action lawsuit against the three makers of analog insulin drug products - Sanofi, Novo Nordisk and Eli Lilly - for exponentially raising consumer insulin prices...

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

Express Scripts, Cigna Opt Out of Paying for EpiPen Competitor Auvi-Q

It's unclear how much of the hefty $4,500 price pharmacy benefit managers or insurers will agree to pay to keep Auvi-Q free for most patients.

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron Pharmaceuticals Could Be Ready to Rebound

Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

5 Rocket Stocks for 2017 -- Amgen, eBay, More

5 Rocket Stocks for 2017 -- Amgen, eBay, More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

TheStreet Quant Rating: C+ (Hold)